サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がん診断における人工知能の世界市場：2023～2030年
市場調査レポート
商品コード
1351021

がん診断における人工知能の世界市場：2023～2030年

Global Artificial Intelligence in Cancer Diagnostics Market 2023-2030

出版日
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
がん診断における人工知能の世界市場：2023～2030年
出版日: 2023年09月06日
発行: Orion Market Research
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん診断における人工知能市場は、予測期間中（2023～2030年）にCAGR 32.5％で成長すると予測されています。がん診断における人工知能（AI）は、早期がん診断に使用される自動化ソフトウェアであり、早期段階でがんを検出することで、患者に適切な治療を提供することができ、その結果、死亡率が低下します。いくつかの政府はヘルスケア情報技術（IT）支出を増やしており、その結果、世界中のヘルスケア・インフラが改善されています。例えば、米国連邦政府のヘルスケアIT支出は、2020年の1,195億米ドルから2021年には1,765億米ドルに増加しました。がん診断における人工知能の支援技術の採用を増やすために政府によって実施されるイニシアチブの増加は、市場の成長を後押しすると予想されます。

セグメント別展望

乳がんサブセグメントががん診断における人工知能の世界市場でかなりのシェアを占めると予測される

タイプ別では、乳がんサブセグメントが市場のかなりのシェアを占めると予想されます。この成長は、世界的に乳がんの症例が増加していることに起因しています。世界保健機関（WHO）によると、2021年には乳がんによる新規症例は230万件以上、死亡者数は68万5,000人以上と推定されています。また、乳がんの約半数は、特定の危険因子を持たない女性に発生します。したがって、乳がんを早期段階で検出するためにAIやMLなどの先進技術を活用することは、業界の成長にさらに貢献しています。早期段階でのがんの発見により、患者に適切な治療を提供することができ、死亡率が低くなります。

地域別展望

がん診断における人工知能の世界市場はさらに、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別に区分されます。なかでも北米は、世界中でがん患者数が増加していることから、世界市場で突出したシェアを占めると予想されています。Canadian Cancer Statisticsによると、カナダでは女性の43％、男性の45％が一生のうちにがんにかかるといわれています。とはいえ、この問題に立ち向かうため、同国はヘルスケア業界全体でAIを積極的に導入しています。

アジア太平洋地域は、がん診断における人工知能の世界市場において著しいCAGRで成長すると予想される

アジア太平洋地域は、予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、健康分野におけるAIとMLの採用が増加していること、また、同地域におけるいくつかの政府の取り組みが、政府だけでなく民間組織による投資の増加につながっていることに起因しています。また、同地域におけるがん患者の増加は、早期診断のためのヘルスケアにおけるAI導入の促進要因となっています。Indian Council of Medical Research-National Cancer Registry Programme（ICMR-NCRP）によると、同国のがん患者数は2022年の1,770万米ドルから2025年には1,900万米ドルに増加すると政府は議会に報告しています。例えば、インド政府の公共政策シンクタンクであるNITI Aayogは、バイオテクノロジー省と共同で画像バイオバンクの構築を目指しており、20,000人以上の患者プロファイルのがん関連の病理学的および放射線学的画像のデータベースを構築する予定です。

したがって、がん診断市場における人工知能ソリューションの導入に向けた国のシフトはかなり進んでいます。例えば、2022年4月のNCBIの記事によると、AI支援大腸内視鏡検査は、約20％だった従来の大腸内視鏡検査と比較して、腺腫検出率を29％に増加させました。これは、腺腫検出率の1%増加は大腸がん有病率の3%減少と関連していることから重要です。AIは、ゲノミクス、EHR、X線画像、病理学、ソーシャルネットワークなどの多種多様な流れを統合して臨床判断を予測することを可能にし、患者の転帰を改善することが期待されます。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • IBM Corp.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Microsoft Corp.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • がん診断における人工知能の世界市場：用途別
    • スクリーニングと診断
    • 腫瘍同定
    • サーベイランス
  • がん診断における人工知能の世界市場：タイプ別
    • 乳がん
    • 前立腺がん
    • 肺がん
    • 大腸がん
    • その他（子宮頸がん、血液がん、骨がん、その他）
  • がん診断における人工知能の世界市場：エンドユーザー別
    • 病院
    • 診断センター
    • 研究機関
    • 医療機関および学術機関

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Therapixel
  • Sophia Genetics SA
  • Freenome Holdings, Inc.
  • Tempus Labs, Inc.
  • Janssen Pharmaceuticals
  • Path AI Inc.
  • DeepMind Technologies Ltd.
  • Cerner Corp.
  • RaySearch Laboratories
  • Flatiron health
  • Whiterabbit.ai
  • Oncology Analytics Inc.
  • Oncora Medical
  • Ibex Medical Analytics Ltd.
  • 4basecare Onco Solutions Pvt. Ltd .
図表

LIST OF TABLES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS BY HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 22. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 24. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTICS MARKET SHARE ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027621

Title: Global Artificial Intelligence in Cancer Diagnostics Market Size, Share & Trends Analysis Report by Application (Screening & Diagnosis, Tumor Identification and Surveillance), by type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Others (Cervical Cancer, blood cancer, bone cancer and other)), and by End User (Hospitals, Diagnostic centers, Research Organization, Medical Institute and academics),Forecast Period (2023-2030).

The global artificial intelligence in cancer diagnostics market is anticipated to grow at a CAGR of 32.5% during the forecast period (2023-2030). Artificial Intelligence (AI) in cancer diagnostics is an automated software used for early cancer diagnostics with the help of cancer detection at early stages, proper treatment can be provided to the patients, resulting in low death rates. Several governments have increased their healthcare Information Technology (IT) expenditure, which in turn to improve healthcare infrastructure around the globe. For instance, the healthcare IT spending of the US federal government increased from $119.5 billion in 2020 to $176.5 billion in 2021. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis is expected to boost the market growth.

Segmental Outlook

The global artificial intelligence in cancer diagnostics market is segmented on the application, type, and End user. Based on the application, the market is sub-segmented into screening & diagnosis, tumor identification and surveillance. Based on the type, the market is sub-segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, and others including cervical cancer, blood cancer, and bone cancer. Further, on the basis of end user, the market is sub-segmented into hospitals, diagnostic centers, research organization, medical institute and academics. Among the end user, the diagnostic centers sub-segment is anticipated to hold a considerable share of the market owing to the increasing government initiatives and funding in healthcare sector.

The Breast Cancer Sub-Segment is Anticipated to Hold a Considerable Share of the Global Artificial Intelligence in Cancer Diagnostics Market

Among the type, the breast cancer sub-segment is expected to hold a considerable share of the market. This growth is attributed to the growing cases of breast cancer globally. According to the World Health Organization (WHO), over 2.3 million new cases and 685,000 fatalities due to breast cancer were estimated in 2021. Additionally, around half of all breast cancers occur in women along with no specific risk factors. Thus, utilizing advanced technologies such as AI & ML in detecting breast cancer supports at early stages further contributing to the industry growth. With the detection of cancer at early stages, proper treatment can be provided to the patients, resulting in low death rates.

Regional Outlook

The global artificial intelligence in cancer diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the rising number of cancer cases around the globe. According to Canadian Cancer Statistics, 43% of women and 45% of men in Canada would have cancer in their lifetime. Nevertheless, to combat this problem, the country is actively adopting AI across the healthcare industry.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Artificial Intelligence in Cancer Diagnostics Market

The Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to an increasing adoption of AI and ML in health and several government initiatives in the region lead to an increase in investment by government as well as private organizations. Also increasing cases of cancer in the region is a driving factor for AI adoption in healthcare for early diagnostics. According to Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP), the government informed Parliament the number of cancer cases in the country is projected to go up from $17.7 million in 2022 to $19.0 million in 2025. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients.

Hence, there is considerable shift of the country towards the adoption of the Artificial Intelligence in Cancer Diagnostics market solutions. For instance, according to an article by the NCBI in April 2022, AI-assisted colonoscopy increased the adenoma detection rate to 29% as compared to conventional colonoscopy, which was about 20%. This is important as 1% increase in adenoma detection rate is associated with 3% decrease in colorectal cancer prevalence. AI allows the integration of a wide variety of streams such as genomics, EHR, radiographic images, pathology, and social networks to predict clinical decisions, which is expected to improve patient outcome.

Market Players Outlook

The major companies serving the artificial intelligence in cancer diagnostics market include: IBM Corp, Intel Corp, Pfizer Inc., Microsoft Corp, Janssen Pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PathAI completed the acquisition of Poplar Healthcare PLLC, an independent anatomic pathology laboratory services provider. Through this acquisition, the company would be able to integrate testing services into its existing artificial intelligence-powered pathology platform. Poplar offers specialized testing services in a range of areas, from oncology to women's health to dermatology.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global artificial intelligence in cancer diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. IBM Corp.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Microsoft Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Artificial Intelligence in Cancer Diagnostics Market by Application
    • 4.1.1. Screening & Diagnosis
    • 4.1.2. Tumor Identification
    • 4.1.3. Surveillance
  • 4.2. Global Artificial Intelligence in Cancer Diagnostics Market by Type
    • 4.2.1. Breast Cancer
    • 4.2.2. Prostate Cancer
    • 4.2.3. Lung Cancer
    • 4.2.4. Colorectal Cancer
    • 4.2.5. Others (Cervical Cancer, Blood Cancer, Bone Cancer, and Other)
  • 4.3. Global Artificial Intelligence in Cancer Diagnostics Market by End User
    • 4.3.1. Hospitals
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research Organization
    • 4.3.4. Medical Institute and Academics

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Therapixel
  • 6.2. Sophia Genetics SA
  • 6.3. Freenome Holdings, Inc.
  • 6.4. Tempus Labs, Inc.
  • 6.5. Janssen Pharmaceuticals
  • 6.6. Path AI Inc.
  • 6.7. DeepMind Technologies Ltd.
  • 6.8. Cerner Corp.
  • 6.9. RaySearch Laboratories
  • 6.10. Flatiron health
  • 6.11. Whiterabbit.ai
  • 6.12. Oncology Analytics Inc.
  • 6.13. Oncora Medical
  • 6.14. Ibex Medical Analytics Ltd.
  • 6.15. 4basecare Onco Solutions Pvt. Ltd .